Get the Stockscreener App
3.87
5.38%
-0.22
After Hours:
3.68
-0.19
-4.91%
Ataibeckley Inc stock is traded at $3.87, with a volume of 5.56M.
It is down -5.38% in the last 24 hours and up +0.00% over the past month.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
See More
Previous Close:
$4.09
Open:
$4.19
24h Volume:
5.56M
Relative Volume:
1.12
Market Cap:
$1.41B
Revenue:
$2.59M
Net Income/Loss:
$-137.89M
P/E Ratio:
-4.7778
EPS:
-0.81
Net Cash Flow:
$-69.76M
1W Performance:
-4.91%
1M Performance:
+0.00%
6M Performance:
+40.73%
1Y Performance:
+141.88%
1-Day Range:
$3.78
$4.19
1-Week Range:
$3.78
$4.19
52-Week Range:
$1.15
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
Name
Ataibeckley Inc
Sector
Industry
Phone
49 89 2153 9035
Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Beckley N V
|
3.87 | 1.49B | 2.59M | -137.89M | -69.76M | -0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Ataibeckley Inc Stock (ATAI) Latest News
Atai Beckley N.V Financial Disclosures & Filings - TradingView — Track All Markets
AtaiBeckley completes redomiciliation from Netherlands to US - Proactive financial news
AtaiBeckley Completes Redomiciliation to the United States - The Manila Times
AtaiBeckley Inc. Completes Redomiciliation from Netherlands to Delaware, Streamlining Corporate Structure - Quiver Quantitative
Why a mental health drug maker just moved its legal home to Delaware - Stock Titan
Ataibeckley completes redomiciliation to the US - MSN
Net current asset value per share of Atai Beckley N.V – GETTEX:9VC - TradingView — Track All Markets
JonesTrading highlights differentiated pipeline at Atai Beckley NV (ATAI) - MSN
JonesTrading Highlights Differentiated Pipeline at Atai Beckley N.V. (ATAI) - Insider Monkey
Psychedelics stocks could benefit from marijuana rescheduling: Jefferies - MSN
13 Best Get Rich Fast Stocks to Buy Right Now - Insider Monkey
The 1 riskiest investment that paid off in 2025 - MSN
Atai Life Sciences (ATAI): Assessing an Expensive-Looking Valuation After a Strong Share Price Run - Yahoo Finance UK
Jones Trading Initiates Coverage of Atai Beckley N.V. (ATAI) with Buy Recommendation - Nasdaq
JonesTrading Initiates Coverage on ATAI Life Sciences With Buy Rating, $16 Price Target - marketscreener.com
Jones Trading initiates Buy rating on atai Life Sciences stock with $16 target - Investing.com
AtaiBeckley joins the Nasdaq Biotechnology Index - Proactive financial news
Atai Beckley Added to Nasdaq Biotechnology Index - marketscreener.com
Atai Beckley N.V. Added to NASDAQ Biotechnology Index, Marking a Significant Milestone for the Company - Quiver Quantitative
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Mental health drug developer joins key Nasdaq biotech index - Stock Titan
MarketBeat's Top 5 Rated Small-Cap Stocks - Finviz
Atai Beckley N.V.(NasdaqGM: ATAI) added to NASDAQ Biotechnology Index - marketscreener.com
H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion - MSN
How Does Atai (ATAI)’s New EMP-01 Patent Shape Its Psychedelic Therapy Moat? - simplywall.st
Atai Life Sciences NV (ATAI) secures patent for social anxiety disorder formulation - MSN
Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation - Finviz
CapEx per share of Atai Beckley N.V – LSX:A3CSB4 - TradingView — Track All Markets
New EMP-01 Patent Win Could Be A Game Changer For Atai Beckley (ATAI) - simplywall.st
ATAI Beckley Secures US Patent for EMP-01 to Treat Social Anxiety Disorder; Shares Up Pre-Bell - marketscreener.com
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio - The Manila Times
AtaiBeckley (NASDAQ: ATAI) gains EMP-01 patent, eyes Phase 2a data in 2026 - Stock Titan
Atai Beckley files prospectus supplement for registered shares after Beckley Psytech acquisition By Investing.com - Investing.com South Africa
Atai Beckley files prospectus supplement for registered shares after Beckley Psytech acquisition - Investing.com Australia
ATAI Life Sciences Files Prospectus for Share Registration - TipRanks
Atai Beckley N.V. Files Prospectus Supplement for Common Shares - TradingView — Track All Markets
Atai Life Sciences (ATAI): Assessing an 8.8x Price-to-Book Valuation After a Volatile Share Price Run - Yahoo Finance
Atai Beckley (ATAI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
ATAIAtai Beckley N.V Short Interest - Finviz
ATAI Life Sciences Files Prospectus for Share Resale - MSN
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates - ADVFN
Form 8-KCurrent report - ADVFN
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - ADVFN
[Form 4] Atai Beckley N.V. Insider Trading Activity - Stock Titan
Atai Beckley N.V. (ATAI) latest stock news and headlines - Yahoo Finance UK
AtaiBeckley advances BPL-003 toward Phase 3 After Strong Phase 2 Data topline data i - Proactive financial news
9 Oversold Biotech Stocks to Invest In - Insider Monkey
Ataibeckley Inc Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):